Trials
7 active
26 in total · 9 in the EU
Targets
—
None known yet
What this is
- How it works
- Aldosterone synthase inhibitor
- Tested for
- Chronic Kidney Disease and Hypertension (3 trials), Primary Hyperaldosteronism, Uncontrolled Hypertension, Heart Failure
- Main trialPhase 3
- “Parent study: This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and achieving normalization of the Renin Angiotensin Aldosterone System (RAAS) in approximately 250 participants ≥ 18 years of age with Primary Aldosteronism (PA), with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics. Baxdrostat (or placebo) will be administered once daily, up-titrated after…”In the company’s words, NCT07007793 on ClinicalTrials.gov
- Other names
- CIN-107 · RO6836191 · Baxfendy
Other drugs for Chronic Kidney Disease and Hypertension
- MT1013Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
- Migalastat HClAmicus Therapeutics · Phase 3
- VicadrostatBoehringer Ingelheim · Phase 3
- XyloCore StrenghtIperboreal Pharma Srl · Phase 3
- TegoprubartEledon Pharmaceuticals · Phase 3
Coming up6
- 10 DecPhase 2 trial completes · ClinicalTrials.gov
- 27 Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- 9 Feb 2028Phase 3 trial completes · ClinicalTrials.gov
- 24 Feb 2028Phase 3 trial completes · ClinicalTrials.gov
- 17 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
- 18 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
FDA approvals1
- 15 May 2026BAXFENDY ASTRAZENECA AB · Application NDA219878
Trials26
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 27 Jul 2027 | Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study. | |
| Phase 3Recruiting | 9 Feb 2028 | A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension. | |
| Phase 3Active, not recruiting | 24 Feb 2028 | A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. | |
| Phase 3Recruiting | 17 Dec 2029 | Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | |
| Phase 3Recruiting | 18 Dec 2029 | A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure | |
| Phase 2Active, not recruiting | 10 Dec 2026 | A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | |
| Phase 3Completed | 21 May 2025 | A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension | |
| Phase 3Completed | 17 Aug 2025 | A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension | |
| Phase 3Completed | 24 Nov 2025 | A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension | |
| Phase 2Completed | 14 Jun 2022 | A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) | |
| Phase 2Completed | 13 Sep 2022 | A Study of CIN-107 in Patients With Uncontrolled Hypertension | |
| Phase 2Completed | 7 Nov 2023 | Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124 | |
| Phase 2Completed | 2 May 2024 | A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease | |
| Phase 2Completed | 28 Oct 2024 | A Study of CIN-107 in Adults With Primary Aldosteronism | |
| Phase 2Completed | 4 Dec 2024 | A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension | |
| Phase 1Completed | 3 Apr 2020 | Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects | |
| Phase 1Completed | 29 Apr 2020 | Baxdrostat Bioavailability and Bioequivalence Study | |
| Phase 1Completed | 12 Dec 2020 | Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects | |
| Phase 1Completed | 30 Apr 2021 | Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function | |
| Phase 1Completed | 15 Jan 2022 | Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat | |
| Phase 1Completed | 15 Apr 2022 | Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment | |
| Phase 1Completed | 20 Sep 2022 | Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population | |
| Phase 1Completed | 13 May 2024 | A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants | |
| Phase 1Completed | 17 Jun 2024 | A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants | |
| Phase 1Completed | 3 Feb 2025 | A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential | |
| Phase 2Authorised | not given | A Proof of Concept, Single Arm, Open Label Study to Assess the Value of SBP response to Baxdrostat as a Discrimination Tool for Primary Aldosteronism in Newly Diagnosed Adults with Untreated Hypertension (BaxDetect) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026